Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7788-7799

  Mapelli, Claudio ^a   Natarajan, Sesha I ^a   Meyer, Jean Philippe ^a   Bastos, Margarita M ^a   Bernatowicz, Michael S ^a   Lee, Ving G ^a   Pluscec, Jelka ^a   Riexinger, Douglas J ^a   Sieber McMaster, Ellen S ^a   Constantine, Keith L ^a   Smith Monroy, Constance A ^a   Golla, Rajasree ^a   Ma, Zhengping ^a   Longhi, Daniel A ^a   Shi, Dan ^a   Xin, Li ^a   Taylor, Joseph R ^a   Koplowitz, Barry ^a   Chi, Cecilia L ^a   Khanna, Ashish ^a   Robinson, Gordon W ^a   Seethala, Ramakrishna ^a   Antal Zimanyi, Ildiko A ^a   Stoffel, Robert H ^a   Han, Songping ^a   Whaley, Jean M ^a   Huang, Christine S ^a   Krupinski, John ^a   Ewing, William R ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SYNTHESIS; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEIN CONFORMATION; RECEPTORS, GLUCAGON;

EID: 72249115356     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900752a     Document Type: Article

References (38)

1. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047-1053.
2. Holst, J. J.; Orskov, C.; Nielsen, O. V.; Schwartz, T. W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987, 211, 169-174.
3. Kreymann, B.; Williams, G.; Ghatei, M. A.; Bloom, S. R. Glucagon- like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 2, 1300-1304.
4. Mojsov, S.; Weir, G. C.; Habener, J. F. Insulinotropin: glucagonlike peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987, 79, 616-619.
5. Nauck, M. A.; Heimesaat, M. M.; Behle, K.; Holst, J. J.; Nauck, M. S.; Ritzel, R.; Hufner, M.; Schmiegel, W. H. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 2002, 87, 1239-1246.
6. Nauck, M. A.; Niedereichholz, U.; Ettler, R.; Holst, J. J.; Orskov, C.; Ritzel, R.; Schmiegel, W. H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 1997, 273, E981
7. Turton, M. D.; O'Shea, D.; Gunn, I.; Beak, S. A.; Edwards, C. M.; Meeran, K.; Choi, S. J.; Taylor, G. M.; Heath, M. M.; Lambert, P. D.; Wilding, J. P.; Smith, D. M.; Ghatei, M. A.; Herbert, J.; Bloom, S. R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379, 69-72. (Pubitemid 26008136)
8. Davis, H. R., Jr.; Mullins, D. E.; Pines, J. M.; Hoos, L. M.; France, C. F.; Compton, D. S.; Graziano, M. P.; Sybertz, E. J.; Strader, C. D.; Van Heek, M. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obes. Res. 1998, 6, 147-156.
9. Zander, M.; Madsbad, S.; Madsen, J. L.; Holst, J. J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359, 824-830.
10. Drucker, D. J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 2003, 17, 161-171.
11. Larsen, J.; Hylleberg, B.; Ng, K.; Damsbo, P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001, 24, 1416-1421. (Pubitemid 33716430)
12. Vilsboll, T.; Agerso, H.; Krarup, T.; Holst, J. J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 2003, 88, 220-224.
13. Mentlein, R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85, 9-24.
14. Holst, J. J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006, 49, 253-260.
15. Eng, J.; Kleinman, W. A.; Singh, L.; Singh, G.; Raufman, J. P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992, 267, 7402-7405.
16. Buse, J. B.; Henry, R. R.; Han, J.; Kim, D. D.; Fineman, M. S.; Baron, A. D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2628-2635. (Pubitemid 39441462)
17. Green, B. D.; Flatt, P. R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract. Res., Clin. Endocrinol. Metab. 2007, 21, 497-516.
18. Chen, D.; Liao, J.; Li, N.; Zhou, C.; Liu, Q.; Wang, G.; Zhang, R.; Zhang, S.; Lin, L.; Chen, K.; Xie, X.; Nan, F.; Young, A. A.; Wang, M. W. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 943-948.
19. Knudsen, L. B.; Kiel, D.; Teng, M.; Behrens, C.; Bhumralkar, D.; Kodra, J. T.; Holst, J. J.; Jeppesen, C. B.; Johnson, M. D.; de Jong, J. C.; Jorgensen, A. S.; Kercher, T.; Kostrowicki, J.; Madsen, P.; Olesen, P. H.; Petersen, J. S.; Poulsen, F.; Sidelmann, U. G.; Sturis, J.; Truesdale, L.; May, J.; Lau, J. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 937-942.
20. Rink, H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin. Tetrahedron Lett. 1987, 28, 3787-3790.
21. King, D. S.; Fields, C. G.; Fields, G. B. A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int. J. Pept. Protein Res. 1990, 36, 255-266.
22. Gefel, D.; Hendrick, G. K.; Mojsov, S.; Habener, J.; Weir, G. C. Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3′,5′-monophosphate formation. Endocrinology 1990, 126, 2164-2168.
23. Suzuki, S.; Kawai, K.; Ohashi, S.; Mukai, H.; Yamashita, K. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 1989, 125, 3109-3114. (Pubitemid 20010691)
24. Adelhorst, K.; Hedegaard, B. B.; Knudsen, L. B.; Kirk, O. Structure-activity studies of glucagon-like peptide-1. J. Biol. Chem. 1994, 269, 6275-6278.
25. Gallwitz, B.; Witt, M.; Paetzold, G.; Morys-Wortmann, C.; Zimmermann, B.; Eckart, K.; Folsch, U. R.; Schmidt, W. E. Structure/activity characterization of glucagon-like peptide-1. Eur. J. Biochem. 1994, 225, 1151-1156.
26. Siegel, E. G.; Gallwitz, B.; Scharf, G.; Mentlein, R.; Morys-Wortmann, C.; Folsch, U. R.; Schrezenmeir, J.; Drescher, K.; Schmidt, W. E. Biological activity of GLP-1-analogues with N-terminal modifications. Regul. Pept. 1999, 79, 93-102.
27. Deacon, C. F.; Knudsen, L. B.; Madsen, K.; Wiberg, F. C.; Jacobsen, O.; Holst, J. J. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998, 41, 271-278.
28. Ritzel, U.; Leonhardt, U.; Ottleben, M.; Ruhmann, A.; Eckart, K.; Spiess, J.; Ramadori, G. A synthetic glucagon-like peptide-1 analog with improved plasma stability. J. Endocrinol. 1998, 159, 93-102. (Pubitemid 28459271)
29. Knudsen, L. B.; Nielsen, P. F.; Huusfeldt, P. O.; Johansen, N. L.; Madsen, K.; Pedersen, F. Z.; Thogersen, H.; Wilken, M.; Agerso, H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000, 43, 1664-1669.
30. Madsen,K.;Knudsen, L. B.;Agersoe,H.; Nielsen, P. F.;Thogersen, H.;Wilken,M.; Johansen, N. L. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. 2007, 50, 6126-6132.
31. Parker, J. C.; Andrews, K. M.; Rescek, D. M.; Massefski, W., Jr.; Andrews, G. C.; Contillo, L. G.; Stevenson, R. W.; Singleton, D. H.; Suleske, R. T. Structure-function analysis of a series of glucagon-like peptide-1 analogs. J. Pept. Res. 1998, 52, 398-409.
32. Raufman, J. P.; Singh, L.; Singh, G.; Eng, J. Truncated glucagonlike peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J. Biol. Chem. 1992, 267, 21432-21437.
33. Thornton, K.; Gorenstein, D. G. Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 1994, 33, 3532-3539.
34. Murage, E. N.; Schroeder, J. C.; Beinborn, M.; Ahn, J. M. Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorg. Med. Chem. 2008, 16, 10106-10112.
35. Agerso, H.; Jensen, L. B.; Elbrond, B.; Rolan, P.; Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45, 195-202. (Pubitemid 34208381)
36. Elbrond, B.; Jakobsen, G.; Larsen, S.; Agerso, H.; Jensen, L. B.; Rolan, P.; Sturis, J.; Hatorp, V.; Zdravkovic, M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25, 1398-1404. (Pubitemid 41071152)
37. Fineman, M. S.; Shen, L. Z.; Taylor, K.; Kim, D. D.; Baron, A. D. Effectiveness of progressive dose-escalation of exenatide (exendin- 4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab. Res. Rev. 2004, 20, 411-417.
38. Ritzel, R.; Orskov, C.; Holst, J. J.; Nauck, M. A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Doseresponse- relationships. Diabetologia 1995, 38, 720-725. E988.